Prolocor Announces Appointment of Raymond Russo as Chief Commercial Officer

Prolocor Logo

Prolocor, Inc., a healthcare startup developing an innovative precision diagnostic test with the potential to predict the risk of thrombosis by quantifying FcγRIIa (pFCG test), today announced the appointment of Raymond Russo as Chief Commercial Officer. Mr. Russo is a seasoned biotech executive with significant operational, commercial, and strategic leadership experience across cardiovascular and hospital markets.

"Ray is a deeply knowledgeable executive with an impressive track record of success leading commercial initiatives in the cardiovascular market," said Dr. Peter DiBattiste, Co-Founder and CEO of Prolocor. "His passion, operational experience and breadth of expertise will be critical for Prolocor as we prepare for the launch of the Prolocor pFCG diagnostic test in the U.S.”

Mr. Russo joins Prolocor with three decades of commercial and launch experience in both large pharmaceutical and small biotech companies. Most recently, he served as Senior Vice President of Commercialization at Vero Biotech launching the first tankless inhaled nitric oxide system, Genosyl® DS. Earlier in his career, Mr. Russo held leadership roles of increasing responsibility at The Medicines Company and Schering-Plough during which time he supported cardiovascular and hospital product launches for notable brands, including the launch of products like Integrilin®, Zetia®, Vytorin®, Nexterone®, and Kengreal®. Mr. Russo has led and participated in a broad array of capital raises and corporate exits during his career. Ray has a BA in Economics and an MBA in Accounting from Rutgers University. 

"I am excited to be joining the team at Prolocor,” said Ray Russo. "Great science, world-class people and an opportunity to positively impact the care of patients with coronary artery disease made my decision to join Prolocor easy.” 

“We are confident that Ray's commercial talent and expertise combined with his leadership will contribute significantly to our continued success,” said Co-Founder and CSO Dr. David Schneider. “We are excited about this new chapter and look forward to working together towards achieving our goals."


Founded by a team that deeply understands thrombosis and cardiovascular disease, Prolocor is building its strategy around platelet FcγRIIa and embarking on a journey to commercialize an innovative precision diagnostic test that quantifies FcγRIIa on the surface of platelets. For more information on Prolocor, please visit the company's website at and follow us on LinkedIn.


This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans" and similar expressions. Although Prolocor's management believes that the expectations reflected in such forward-looking statements are reasonable, forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Prolocor, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, Prolocor’s planned level of revenues and capital expenditures, Prolocor’s available cash and its ability to obtain additional funding, the uncertainties inherent in research and development, future clinical data and analysis, including post-marketing, decisions by regulatory authorities regarding whether and when to approve any device or application that may be filed for any such product candidates and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates, if approved, may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Prolocor's ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, and risks associated with intellectual property. Other than as required by applicable law, Prolocor does not undertake any obligation to update or revise any forward-looking information or statements.


Source: Prolocor Inc.

About Prolocor Inc

Prolocor is a healthcare startup, building its strategy around a protein on platelets called FcγRIIa, and embarking on a journey to commercialize an innovative precision diagnostic test that quantifies FcγRIIa on the surface of platelets.

Prolocor Inc
2138 Lombard Street , #Unit 4A
Philadelphia, PA


More Press Releases